Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

01-12-2022 | Respiratory Microbiota | Research

Global research trends on the links between the gut microbiome and cancer: a visualization analysis

Authors: Sa’ed H. Zyoud, Samah W. Al-Jabi, Riad Amer, Muna Shakhshir, Moyad Shahwan, Ammar A. Jairoun, Maha Akkawi, Adham Abu Taha

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Significant links between the microbiota and human health have emerged in the last 20 years. A correlation has recently been demonstrated between changes in the gut microbiota and the development of cancer. This study aimed to use bibliometric analysis of the published gut microbiome and cancer literature to present the research status and summarize the hotspots for frontier studies.

Methods

A literature search for research on the gut microbiome and cancer research from 2001 to 2020 was conducted using the Scopus database on 20 March 2021. VOSviewer software (version 1.6.16) was used to perform the visualization analysis.

Results

From 2001 to 2020, a total of 2061 publications were retrieved. Annual publication output grew from 10 in 2001 to 486 in 2020. The USA had the largest number of publications, making the largest contribution to the field (n  = 566, 27.46%). Before 2016, most studies focused on the ‘effect of probiotics on cancer’. The latest trends showed that ‘microbiota composition and gene expression’ and ‘host-microbiome interaction in cancer immunotherapy’ would be more concerned more widely in the future.

Conclusions

Research on ‘microbiota composition and gene expression’ and ‘host-microbiome interaction in cancer immunotherapy’ will continue to be the hotspot. Therefore, this study provides the trend and characteristics of the literature on the gut microbiota and cancer literature, which provided a useful bibliometric analysis for researchers to conduct further research.
Literature
1.
GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544.
2.
3.
Gaucher L, Adda L, Séjourné A, Joachim C, Guillaume C, Poulet C, Liabeuf S, Gras-Champel V, Masmoudi K, Houessinon A, et al. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol. 2021;13:17588359211000592.PubMedPubMedCentral
4.
Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–70.PubMedPubMedCentral
5.
Butterfield LH, Kaufman HL, Marincola FM. Cancer immunotherapy principles and practice. New York: Springer Publishing Company; 2021.
6.
Cheng WY, Wu CY, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut. 2020;69(10):1867–76.PubMed
7.
Gori S, Inno A, Belluomini L, Bocus P, Bisoffi Z, Russo A, Arcaro G. Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. Crit Rev Oncol Hematol. 2019;143:139–47.PubMed
8.
Raza MH, Gul K, Arshad A, Riaz N, Waheed U, Rauf A, Aldakheel F, Alduraywish S, Rehman MU, Abdullah M, et al. Microbiota in cancer development and treatment. J Cancer Res Clin Oncol. 2019;145(1):49–63.PubMed
9.
10.
Yue YY, Fan XY, Zhang Q, Lu YP, Wu S, Wang S, Yu M, Cui CW, Sun ZR. Bibliometric analysis of subject trends and knowledge structures of gut microbiota. World J Clin Cases. 2020;8(13):2817–32.PubMedPubMedCentral
11.
Yao H, Wan JY, Wang CZ, Li L, Wang J, Li Y, Huang WH, Zeng J, Wang Q, Yuan CS. Bibliometric analysis of research on the role of intestinal microbiota in obesity. PeerJ. 2018;6:e5091.PubMedPubMedCentral
12.
Ejtahed HS, Tabatabaei-Malazy O, Soroush AR, Hasani-Ranjbar S, Siadat SD, Raes J, Larijani B. Worldwide trends in scientific publications on association of gut microbiota with obesity. Iran J Basic Med Sci. 2019;22(1):65–71.PubMedPubMedCentral
13.
Zyoud SH, Smale S, Waring WS, Sweileh WM, Al-Jabi SW. Global research trends in microbiome-gut-brain axis during 2009–2018: a bibliometric and visualized study. BMC Gastroenterol. 2019;19(1):158.PubMedPubMedCentral
14.
Zhu X, Hu J, Deng S, Tan Y, Qiu C, Zhang M, Ni X, Lu H, Wang Z, Li L, et al. Bibliometric and visual analysis of research on the links between the gut microbiota and depression from 1999 to 2019. Front Psychiatry. 2020;11:587670.PubMed
15.
Tian J, Li M, Lian F, Tong X. The hundred most-cited publications in microbiota of diabetes research: a bibliometric analysis. Medicine. 2017;96(37):e7338.PubMedPubMedCentral
16.
Li Y, Zou Z, Bian X, Huang Y, Wang Y, Yang C, Zhao J, Xie L. Fecal microbiota transplantation research output from 2004 to 2017: a bibliometric analysis. PeerJ. 2019;7:e6411.PubMedPubMedCentral
17.
Bougioukas KI, Vounzoulaki E, Mantsiou CD, Papanastasiou GD, Savvides ED, Ntzani EE, Haidich AB. Global mapping of overviews of systematic reviews in healthcare published between 2000 and 2020: a bibliometric analysis. J Clin Epidemiol. 2021;137:58–72.PubMed
18.
Du YQ, Zhu GD, Cao J, Huang JY. Research supporting malaria control and elimination in China over four decades: a bibliometric analysis of academic articles published in chinese from 1980 to 2019. Malar J. 2021;20(1):158.PubMedPubMedCentral
19.
Gonzalez-Alcaide G, Palacios-Fernandez S, Ramos-Rincon JM. Thematic research clusters in very old populations (>/= 80 years): a bibliometric approach. BMC Geriatr. 2021;21(1):266.PubMedPubMedCentral
20.
21.
Sahin S, Sivri N, Akpinar I, Cincin ZB, Sonmez VZ. A comprehensive bibliometric overview: antibiotic resistance and Escherichia coli in natural water. Environ Sci Pollut Res Int. 2021;28(25):32256–63.PubMedCentral
22.
Sweileh WM. Contribution of researchers in the Arab region to peer-reviewed literature on mental health and well-being of university students. Int J Ment Health Syst. 2021;15(1):50.PubMedPubMedCentral
23.
Torres RT, Carvalho J, Cunha MV, Serrano E, Palmeira JD, Fonseca C. Temporal and geographical research trends of antimicrobial resistance in wildlife—a bibliometric analysis. One Health. 2021;11:100198.PubMed
24.
Wang K, Duan W, Duan Y, Yu Y, Chen X, Xu Y, Chen H, Huang H, Xiong B. A bibliometric insight of genetic factors in ASD: emerging trends and new developments. Brain Sci. 2020;11(1):1–14.
25.
Zyoud SH. The Arab region’s contribution to global COVID-19 research: bibliometric and visualization analysis. Global Health. 2021;17(1):31.PubMedPubMedCentral
26.
Møller AM, Myles PS. What makes a good systematic review and meta-analysis? Br J Anaesth. 2016;117(4):428–30.PubMed
27.
O’Gorman CS, Macken AP, Cullen W, Saunders J, Dunne C, Higgins MF. What are the differences between a literature search, a literature review, a systematic review and a meta-analysis? And why is a systematic review considered to be so good? Ir Med J. 2013;106(2 Suppl):8–10.PubMed
28.
Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141–6.PubMed
29.
Wallin JA. Bibliometric methods: pitfalls and possibilities. Basic Clin Pharmacol Toxicol. 2005;97(5):261–75.PubMed
30.
31.
Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26(2):91–108.PubMed
32.
Sweileh WM, Moh’d Mansour A. Bibliometric analysis of global research output on antimicrobial resistance in the environment (2000–2019). Glob Health Res Policy. 2020;5:37.PubMedPubMedCentral
33.
Zhang T, Yin X, Yang X, Man J, He Q, Wu Q, Lu M. Research trends on the relationship between microbiota and gastric cancer: a bibliometric analysis from 2000 to 2019. J Cancer. 2020;11(16):4823–31.PubMedPubMedCentral
34.
Baas J, Schotten M, Plume A, Côté G, Karimi R. Scopus as a curated, high-quality bibliometric data source for academic research in quantitative science studies. Quant Sci Stud. 2020;1(1):377–86.
35.
Sweileh WM. Bibliometric analysis of scientific publications on “sustainable development goals” with emphasis on “good health and well-being” goal (2015–2019). Global Health. 2020;16(1):68.PubMedPubMedCentral
36.
van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38.PubMed
37.
van Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017;111(2):1053–70.PubMedPubMedCentral
38.
Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338(6103):120–3.PubMedPubMedCentral
39.
Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE. 2012;7(6):e39743.PubMedPubMedCentral
40.
Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21(4):504–16.PubMedPubMedCentral
41.
42.
Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12(10):661–72.PubMed
43.
Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology. 2004;127(1):80–93.PubMed
44.
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7.PubMed
45.
46.
Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Van Nhieu JT, Furet JP. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE. 2011;6(1):e16393.PubMedPubMedCentral
47.
Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012;6(2):320–9.PubMed
48.
AlRyalat SAS, Malkawi LW, Momani SM. Comparing bibliometric analysis using PubMed, Scopus, and Web of science databases. J Vis Exp. 2019;152:e58494.
49.
Zyoud SH, Al-Jabi SW. Mapping the situation of research on coronavirus disease-19 (COVID-19): a preliminary bibliometric analysis during the early stage of the outbreak. BMC Infect Dis. 2020;20(1):561.PubMedPubMedCentral
50.
Sweileh WM. Bibliometric analysis of global scientific literature on vaccine hesitancy in peer-reviewed journals (1990–2019). BMC Public Health. 2020;20(1):1252.PubMedPubMedCentral
51.
Sweileh WM. Bibliometric analysis of peer-reviewed literature on antimicrobial stewardship from 1990 to 2019. Global Health. 2021;17(1):1.PubMedPubMedCentral
52.
Briones-Bitar J, Carrión-Mero P, Montalván-Burbano N, Morante-Carballo F. Rockfall research: a bibliometric analysis and future trends. Geosciences. 2020;10(10):403.
53.
Falagas ME, Pitsouni EI, Malietzis GA, Pappas G. Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses. FASEB J. 2008;22(2):338–42.PubMed
54.
Kulkarni AV, Aziz B, Shams I, Busse JW. Comparisons of citations in Web of Science, Scopus, and Google Scholar for articles published in general medical journals. JAMA. 2009;302(10):1092–6.PubMed
55.
Mongeon P, Paul-Hus A. The journal coverage of Web of Science and Scopus: a comparative analysis. Scientometrics. 2015;106(1):213–28.
56.
Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Goedert JJ, Hayes RB, Yang L. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105(24):1907–11.PubMedPubMedCentral
57.
Berkovic MC, Cigrovski V, Bilic-Curcic I, Mrzljak A. What is the gut feeling telling us about physical activity in colorectal carcinogenesis? World J Clin Cases. 2020;8(23):5844–51.PubMedPubMedCentral
58.
Contreras AV, Cocom-Chan B, Hernandez-Montes G, Portillo-Bobadilla T, Resendis-Antonio O. Host-microbiome interaction and cancer: potential application in precision medicine. Front Physiol. 2016;7:606.PubMedPubMedCentral
59.
Gupta A, Saha S, Khanna S. Therapies to modulate gut microbiota: past, present and future. World J Gastroenterol. 2020;26(8):777–88.PubMedPubMedCentral
60.
Huang QY, Yao F, Zhou CR, Huang XY, Wang Q, Long H, Wu QM. Role of gut microbiome in regulating the effectiveness of metformin in reducing colorectal cancer in type 2 diabetes. World J Clin Cases. 2020;8(24):6213–28.PubMedPubMedCentral
61.
Malla MA, Dubey A, Kumar A, Yadav S, Hashem A, Abd Allah EF. Exploring the human microbiome: the potential future role of next-generation sequencing in disease diagnosis and treatment. Front Immunol. 2018;9:2868.PubMed
62.
Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271–85.PubMed
63.
Sabit H, Cevik E, Tombuloglu H. Colorectal cancer: the epigenetic role of microbiome. World J Clin Cases. 2019;7(22):3683–97.PubMedPubMedCentral
64.
65.
Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, Hudcovic T, Vannucci L, Tučková L, Rossmann P, Hrnčíř T, Kverka M, Zákostelská Z, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011;8(2):110–20.PubMedPubMedCentral
66.
Wei AL, Li M, Li GQ, Wang X, Hu WM, Li ZL, Yuan J, Liu HY, Zhou LL, Li K, et al. Oral microbiome and pancreatic cancer. World J Gastroenterol. 2020;26(48):7679–92.PubMedPubMedCentral
67.
Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 2001;73(2 Suppl):451s–5s.PubMed
68.
Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014;10(11):766.PubMedPubMedCentral
69.
Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes. 2019;10(3):424–8.PubMed
70.
Kujawska M, Jodynis-Liebert J. Potential of the ellagic acid-derived gut microbiota metabolite—Urolithin A in gastrointestinal protection. World J Gastroenterol. 2020;26(23):3170–81.PubMedPubMedCentral
71.
Russo E, Nannini G, Dinu M, Pagliai G, Sofi F, Amedei A. Exploring the food-gut axis in immunotherapy response of cancer patients. World J Gastroenterol. 2020;26(33):4919–32.PubMedPubMedCentral
72.
Yan C, Tu XX, Wu W, Tong Z, Liu LL, Zheng Y, Jiang WQ, Zhao P, Fang WJ, Zhang HY. Antibiotics and immunotherapy in gastrointestinal tumors: friend or foe? World J Clin Cases. 2019;7(11):1253–61.PubMedPubMedCentral
73.
Yi M, Jiao D, Qin S, Chu Q, Li A, Wu K. Manipulating gut microbiota composition to enhance the therapeutic effect of cancer immunotherapy. Integr Cancer Ther. 2019;18:1534735419876351.PubMedPubMedCentral
Metadata
Title
Global research trends on the links between the gut microbiome and cancer: a visualization analysis
Authors
Sa’ed H. Zyoud
Samah W. Al-Jabi
Riad Amer
Muna Shakhshir
Moyad Shahwan
Ammar A. Jairoun
Maha Akkawi
Adham Abu Taha
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03293-y

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Letter to the Editor

Risk of confounding variables in multivariate analysis

Research

Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA

Research

Elevated mid-trimester 4-h postprandial triglycerides for predicting late-onset preeclampsia: a prospective screening study

Research

The treatment of Qibai Pingfei Capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota

Research

Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial

Research

Association of monocyte-lymphocyte ratio and proliferative diabetic retinopathy in the U.S. population with type 2 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits